Welcome to our dedicated page for Trevi Therapeutics news (Ticker: TRVI), a resource for investors and traders seeking the latest updates and insights on Trevi Therapeutics stock.
Trevi Therapeutics, Inc. reports news on its clinical-stage biopharmaceutical development of Haduvio, an oral extended-release formulation of nalbuphine, for chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. Company updates commonly cover clinical trial results and plans, FDA interactions, medical-conference presentations, intellectual property, and the investigational status of Haduvio.
Trevi also reports financing and corporate updates tied to its development strategy, including common stock offerings, quarterly financial results, cash runway commentary, and participation in healthcare investor events.
Trevi Therapeutics (Nasdaq: TRVI) closed an underwritten public offering of 13,340,000 common shares at $13.00 per share on April 20, 2026, including the full exercise of a 1,740,000-share underwriter option. Gross proceeds were approximately $173 million before underwriting discounts, commissions, and expenses.
The shares were sold by Trevi pursuant to a shelf registration on Form S-3 and the final prospectus supplement has been filed with the SEC.
Trevi Therapeutics (Nasdaq: TRVI) priced an underwritten offering of 11,600,000 common shares at $13.00 per share for approximately $150 million in gross proceeds, with a 30-day underwriter option for up to 1,740,000 additional shares. The offering is expected to close on or about April 20, 2026, subject to customary closing conditions.
The shares are being sold by Trevi under a Form S-3 registration (filed November 13, 2025). Joint book-runners include Morgan Stanley, Leerink Partners, Cantor, and Stifel; Oppenheimer is lead manager.
Trevi Therapeutics (NASDAQ: TRVI) announced on April 16, 2026 that it has commenced an underwritten public offering of $150,000,000 of common stock, with a 30-day option for underwriters to purchase up to an additional $22,500,000.
The offering is subject to market conditions and will be made under its Form S-3 shelf registration; final terms will be disclosed in a prospectus supplement.
Trevi Therapeutics (Nasdaq: TRVI) announced senior management will participate in investor events and an Investor & Analyst Day in April–May 2026. Key appearances include Needham Virtual Healthcare Conference (fireside chat April 13), Raymond James Biotech Symposium (April 14), Oppenheimer Innovation on the Island (April 27–29), and an in-person Analyst Day May 7, 2026 in Midtown New York.
Management attendees include Jennifer Good, President and CEO, and David Hastings, CFO; the Analyst Day will feature key opinion leaders in chronic cough in IPF/ILD and RCC and a virtual webcast option.
Trevi Therapeutics (Nasdaq: TRVI) reported year-end 2025 results and clinical updates on March 17, 2026. The company ended 2025 with $188.3 million in cash and expects runway into 2028. Trevi gained FDA alignment after an End-of-Phase 2 meeting for IPF-related chronic cough and plans two Phase 3 trials, a Phase 2b RCC trial in Q2 2026, and a Phase 2b non‑IPF ILD trial in H2 2026.
Key financials: 4Q25 net loss of $8.3M; full-year 2025 net loss of $42.8M; R&D $33.5M; G&A $15.9M. Management will host a conference call and an Investor Day on May 7, 2026.
Trevi Therapeutics (Nasdaq: TRVI) will report its fourth quarter and year‑end 2025 financial results and provide business updates on March 17, 2026 at 4:30 p.m. ET. Senior management will host a conference call and live audio webcast to review results and corporate developments.
Investors can register via the company website at ir.trevitherapeutics.com/news-events/events; registered phone participants receive unique call‑in details by email. An archived replay will be available for 30 days after the event.
Trevi Therapeutics (NASDAQ: TRVI) reported that it completed an End-of-Phase 2 meeting with the FDA and gained alignment on its development plan for Haduvio (oral nalbuphine ER) in IPF-related chronic cough. Two pivotal Phase 3 trials will run in parallel, with initiation targeted in Q2 2026 and the second in H2 2026. The program also includes remaining Phase 1 studies the company expects to complete to support an NDA.
Both randomized, double-blind, placebo-controlled global trials will test 54 mg BID dosing, use objective 24-hour cough-frequency as the primary endpoint, and randomize patients 2:1 versus placebo.
Trevi Therapeutics (Nasdaq: TRVI) announced senior management will participate in two March 2026 industry events: the Leerink Partners 2026 Global Healthcare Conference in Miami and the Access USA Rare Disease Summit in Philadelphia.
Presentations include a March 11 fireside chat with Jennifer Good and James Cassella and a March 18 panel session featuring Farrell Simon. A live webcast link is provided for the Leerink fireside chat.
Trevi Therapeutics (Nasdaq: TRVI) announced management will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 at 9:20 a.m. ET.
Jennifer Good, President and CEO, and David Hastings, CFO, will speak and hold investor meetings during the virtual conference Feb 25–26. Trevi is a clinical-stage biopharmaceutical developing Haduvio (oral nalbuphine ER) for chronic cough in IPF, non-IPF ILD, and refractory chronic cough.
Trevi Therapeutics (Nasdaq: TRVI) announced that key Phase 2b CORAL trial results for oral nalbuphine ER in idiopathic pulmonary fibrosis (IPF) chronic cough were published in JAMA on Jan 22, 2026. The trial showed a statistically significant reduction in 24-hour objective cough frequency across all dose groups at Week 6, with significant effects as early as Week 2. More than 60% of treated patients achieved ≥50% reduction in 24-hour cough frequency at Week 6. Patient-reported outcomes aligned with objective monitoring. Safety was consistent with prior data; discontinuations due to adverse events were 6% in treated groups versus 5% for placebo.